B-intervention	0	10	Ultrasound
O	11	13	is
O	14	16	at
O	17	22	least
O	23	25	as
O	26	30	good
O	31	33	as
B-control	34	42	magnetic
I-control	43	52	resonance
I-control	53	60	imaging
O	61	63	in
O	64	74	predicting
O	75	81	tumour
O	82	86	size
O	87	91	post
O	91	92	-
O	92	103	neoadjuvant
O	104	116	chemotherapy
O	117	119	in
O	120	126	breast
O	127	133	cancer
O	133	134	.

O	135	138	The
O	139	142	aim
O	143	145	of
O	146	150	this
O	151	156	study
O	157	160	was
O	161	163	to
O	164	172	evaluate
O	173	176	the
O	177	185	accuracy
O	186	188	of
O	189	197	clinical
O	198	205	imaging
O	206	208	of
O	209	212	the
O	213	220	primary
O	221	227	breast
O	228	234	tumour
O	235	239	post
O	239	240	-
O	240	251	neoadjuvant
O	252	264	chemotherapy
O	265	266	(
O	266	269	NAC
O	269	270	)
O	271	278	related
O	279	281	to
O	282	285	the
O	286	290	post
O	290	291	-
O	291	302	neoadjuvant
O	303	315	histological
O	316	322	tumour
O	323	327	size
O	328	329	(
O	329	333	gold
O	334	342	standard
O	342	343	)
O	344	347	and
O	348	355	whether
O	356	360	this
O	361	367	varies
O	368	372	with
O	373	379	breast
O	380	386	cancer
O	387	394	subtype
O	394	395	.

O	396	398	In
O	399	403	this
O	404	409	study
O	409	410	,
O	411	418	results
O	419	421	of
O	422	426	both
O	427	435	magnetic
O	436	445	resonance
O	446	453	imaging
O	454	455	(
O	455	458	MRI
O	458	459	)
O	460	463	and
O	464	474	ultrasound
O	475	476	(
O	476	478	US
O	478	479	)
O	480	484	were
O	485	493	reported
O	493	494	.

B-eligibility	495	503	Patients
I-eligibility	504	508	with
I-eligibility	509	517	invasive
I-eligibility	518	524	breast
I-eligibility	525	531	cancer
O	532	536	were
O	537	545	enrolled
O	546	548	in
O	549	552	the
O	553	559	INTENS
O	560	565	study
O	566	573	between
O	574	578	2006
O	579	582	and
O	583	587	2009
O	587	588	.

O	589	591	We
O	592	600	included
B-total-participants	601	604	182
O	605	613	patients
O	613	614	,
O	615	617	of
O	618	622	whom
O	623	627	data
O	628	632	were
O	633	642	available
O	643	646	for
O	647	651	post
O	651	652	-
O	652	655	NAC
O	656	659	MRI
O	660	661	(
O	661	662	n
O	662	663	=
B-control-participants	663	666	155
O	666	667	)
O	667	668	,
O	669	671	US
O	672	673	(
O	673	674	n
O	674	675	=
B-intervention-participants	675	678	123
O	678	679	)
O	679	680	,
O	681	684	and
O	685	702	histopathological
O	703	709	tumour
O	710	714	size
O	714	715	.

O	716	719	MRI
O	720	729	estimated
B-outcome	730	738	residual
I-outcome	739	745	tumour
I-outcome	746	750	size
I-outcome	751	755	with
I-outcome	756	757	<
I-outcome	757	759	10
I-outcome	759	760	-
I-outcome	760	762	mm
I-outcome	763	774	discordance
O	775	777	in
B-cv-bin-percent	778	780	54
I-cv-bin-percent	780	781	%
O	782	784	of
O	785	793	patients
O	793	794	,
B-outcome	795	808	overestimated
I-outcome	809	813	size
O	814	816	in
B-cv-bin-percent	817	819	28
I-cv-bin-percent	819	820	%
O	821	824	and
B-outcome	825	839	underestimated
I-outcome	840	844	size
O	845	847	in
B-cv-bin-percent	848	850	18
I-cv-bin-percent	850	851	%
O	852	854	of
O	855	863	patients
O	863	864	.

O	865	869	With
O	870	872	US
O	872	873	,
O	874	878	this
O	879	882	was
B-iv-bin-percent	883	885	63
I-iv-bin-percent	885	886	%
O	886	887	,
B-iv-bin-percent	888	890	20
I-iv-bin-percent	890	891	%
O	892	895	and
B-iv-bin-percent	896	898	17
I-iv-bin-percent	898	899	%
I-iv-bin-percent	899	900	,
O	901	913	respectively
O	913	914	.

O	915	918	The
B-outcome	919	927	negative
I-outcome	928	938	predictive
I-outcome	939	944	value
O	945	947	in
O	948	955	hormone
O	956	964	receptor
O	964	965	-
O	965	973	positive
O	974	981	tumours
O	982	985	for
O	986	990	both
O	991	994	MRI
O	995	998	and
O	999	1001	US
O	1002	1005	was
O	1006	1009	low
O	1009	1010	,
B-cv-bin-percent	1011	1013	26
I-cv-bin-percent	1013	1014	%
O	1015	1018	and
B-iv-bin-percent	1019	1021	33
I-iv-bin-percent	1021	1022	%
O	1022	1023	,
O	1024	1036	respectively
O	1036	1037	.

O	1038	1041	The
B-outcome	1042	1048	median
I-outcome	1049	1058	deviation
I-outcome	1059	1061	in
I-outcome	1062	1070	clinical
I-outcome	1071	1077	tumour
I-outcome	1078	1082	size
O	1083	1085	as
O	1086	1096	percentage
O	1097	1099	of
O	1100	1112	pathological
O	1113	1119	tumour
O	1120	1123	was
B-cv-cont-median	1124	1126	63
I-cv-cont-median	1126	1127	%
O	1128	1129	(
O	1129	1132	P25
O	1132	1133	=
O	1133	1135	26
O	1135	1136	,
O	1137	1140	P75
O	1140	1141	=
O	1141	1144	100
O	1144	1145	)
O	1146	1149	and
B-iv-cont-median	1150	1152	49
I-iv-cont-median	1152	1153	%
O	1154	1155	(
O	1155	1158	P25
O	1158	1159	=
O	1159	1161	22
O	1161	1162	,
O	1163	1166	P75
O	1166	1167	=
O	1167	1170	100
O	1170	1171	)
O	1172	1175	for
O	1176	1179	MRI
O	1180	1183	and
O	1184	1186	US
O	1186	1187	,
O	1188	1200	respectively
O	1201	1202	(
O	1202	1203	P
O	1203	1204	=
O	1204	1205	0
O	1205	1206	.
O	1206	1208	06
O	1208	1209	)
O	1209	1210	.

O	1211	1213	In
O	1214	1218	this
O	1219	1224	study
O	1224	1225	,
O	1226	1228	US
O	1229	1232	was
O	1233	1235	at
O	1236	1241	least
O	1242	1244	as
O	1245	1249	good
O	1250	1252	as
O	1253	1259	breast
O	1260	1263	MRI
O	1264	1266	in
O	1267	1276	providing
O	1277	1288	information
O	1289	1291	on
O	1292	1300	residual
O	1301	1307	tumour
O	1308	1312	size
O	1313	1317	post
O	1317	1318	-
O	1318	1329	neoadjuvant
O	1330	1342	chemotherapy
O	1342	1343	.

O	1344	1351	However
O	1351	1352	,
O	1353	1357	both
O	1358	1368	modalities
O	1369	1377	suffered
O	1378	1382	from
O	1383	1384	a
O	1385	1396	substantial
O	1397	1407	percentage
O	1408	1410	of
O	1411	1415	over
O	1415	1416	-
O	1417	1420	and
O	1421	1436	underestimation
O	1437	1439	of
O	1440	1446	tumour
O	1447	1451	size
O	1452	1455	and
O	1456	1458	in
O	1459	1467	addition
O	1468	1472	both
O	1473	1479	showed
O	1480	1481	a
O	1482	1485	low
O	1486	1494	negative
O	1495	1505	predictive
O	1506	1511	value
O	1512	1514	of
O	1515	1525	pathologic
O	1526	1534	complete
O	1535	1544	remission
O	1545	1546	(
O	1546	1549	Gov
O	1550	1552	nr
O	1552	1553	:
O	1554	1565	NCT00314977
O	1565	1566	)
O	1566	1567	.
